In brief
Telepharmacy in Thailand has moved from the development of the regulatory framework to its implementation phase. With the FDA's telepharmacy framework now in place and telepharmacy platforms entering the market, the focus is increasingly turning to how businesses can participate in this emerging healthcare ecosystem. As pharmacies, digital platforms, and delivery providers come together under a regulated model, telepharmacy is becoming an increasingly important component of Thailand's digital health landscape.
In more detail
The telepharmacy framework enables pharmacies that have obtained the necessary approvals to provide telepharmacy services through digital platforms which have been approved by the FDA, including pharmacist consultations, medication counselling, and the supply and delivery of medicines. The initiative is intended to improve access to pharmaceutical care, particularly for elderly patients, individuals with chronic diseases, and those in remote areas, while maintaining appropriate standards of professional practice and patient safety.
The significance of telepharmacy extends well beyond the pharmacy sector. By bringing together healthcare providers, digital platforms, e-commerce operators, and delivery networks within a regulated framework, telepharmacy has the potential to reshape how pharmaceutical care is accessed and delivered in Thailand. Businesses exploring this space should consider not only the commercial opportunities arising from evolving healthcare delivery models but also the regulatory considerations associated with digitally enabled healthcare services.
Telepharmacy represents an important step in Thailand's digital health evolution. As regulatory frameworks mature and market participation continues to grow, the sector is expected to create new opportunities for innovation and collaboration across the healthcare value chain. Businesses that understand the evolving landscape early may be best positioned to participate in the next phase of digital healthcare delivery in Thailand.
Whilst the telepharmacy framework provides clearer guidance for business operators wishing to operate this new business model, it remains important to note that the telepharmacy framework does not change existing laws related to the sales of pharmaceutical products in Thailand. Pharmaceutical products (other than household drugs) must still be sold in accordance with existing requirements (i.e., the sales must be made through duly licensed pharmacies). This means that there is not yet a regulatory framework permitting pharmaceutical products to be sold entirely through online channels, including e-commerce platforms.
About our Regulatory Affairs Services Department
Baker McKenzie's Regulatory Affairs Services Department (RASD) advises clients on how to satisfy regulatory obligations with respect to the launch of products into the Thai market. This initiative was designed to position clients at a comparative strategic advantage and enhance their opportunities for success in Thailand's growing food, biotech, pharmaceutical and healthcare sectors.
The RASD team consists of five professionals trained in food science, pharmaceutical science, and medical science who bring decades of industry-specific knowledge, understanding, and experience to bear for clients in this hyper-competitive and closely regulated industry sector. The areas of expertise cover the regulations of the Food and Drug Administration (FDA), the Department of Livestock Development, the Thai Industrial Standards Institute, the Department of Medical Science, the Office of the Consumer Protection Board, and other related fields.
* * * * *
Praween Chantanakomes, Senior Associate, and Prim Uditananda, Regulatory Affairs Manager, have contributed to this legal update.